Understanding how time perception affects the sense of self in schizophrenia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the disturbances in the sense of self and time perception in patients with schizophrenia. It aims to identify objective markers that can predict the onset of psychosis in individuals showing minimal symptoms. The methodology involves tactile stimulation and assessments of how patients utilize their perception of time to prepare for future events. By understanding these correlations, the study seeks to improve management strategies for at-risk individuals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or Female;
* Age between 18 and 60 years inclusive;
* Subject who has dated and signed the consent form (guardian or custodian prior to the commencement of any trial-related procedures if applicable);
* Enrolled in a social security plan or beneficiary of such a plan.

Exclusion Criteria:

* Psychoactive substance use disorders (as defined by DSM-V);
* Use of benzodiazepines (in the period prior to inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (in the 2 months prior to inclusion; use of cannabis (THC) will be verified with a urine dipstick) or hallucinogenic substances (in the period prior to inclusion, for a duration equivalent to 5 half-lives of the product);
* Neurological pathology or sequelae;
* Attention deficit hyperactivity disorder (ADHD);
* A borderline personality disorder;
* Disabling sensory disorders;
* Person deprived of liberty or under court protection;
* Pregnant, parturient or nursing woman;
* Subject in a period of exclusion as defined by another clinical study.

Where it's running

• Anne GIERSCH
  Strasbourg, France Recruiting

Study contacts

• Principal investigator: Anne GIERSCH, MD, PhD — Institut National de la Santé Et de la Recherche Médicale, France
• Study coordinator: Anne GIERSCH, MD PhD
• Email: anne.giersch@inserm.fr
• Phone: 0388116471

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Lumateperone to improve motivation in patients with schizophrenia and psychosis

  This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.

  Recruiting Phase 3 Louisiana State University Health Sciences Center Shreveport · Shreveport, Louisiana · NCT06482554

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• XEP527 in stable schizophrenia: safety and how it behaves in the body

  This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.

  Recruiting Phase 1 Novartis · Bentonville, Arkansas · NCT07908680

• Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations

  This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.

  Recruiting Ciusss de L'Est de l'Île de Montréal · Montreal, Quebec · NCT07902518

• Quality of life and safety in quetiapine use for schizophrenia or bipolar disorder

  This study looks at how patients with schizophrenia or bipolar disorder feel and stay safe when treated with quetiapine alone or with other antipsychotics.

  Recruiting Bosnalijek D.D · Sarajevo · NCT07858565

• Neuronavigated rTMS for treatment-resistant auditory hallucinations

  We are testing whether personalized neuronavigated inhibitory rTMS can reduce persistent auditory verbal hallucinations in adults who don’t respond to medication.

  Recruiting Psychiatric University Hospital, Zurich · Zurich · NCT07856368

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.